Avatrombopag would not compete with TPO for binding for the TPO receptor and it has an additive impact with TPO on platelet creation. Suggest QTc prolongation consequences >20 ms will not be expected with the very best recommended therapeutic dosing routine depending on Evaluation of knowledge in the pooled scientific https://jamesj318afi1.wikiadvocate.com/user